Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

347 ARTÍCULOS , VIENDO DEL 271 AL 285

[Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer's disease: friend or foe?]

Kovacs J, Pakaski M, Juhasz A, Feher A, Drotos G, Fazekas CO, Horvath TL, Janka Z, Kalman J.

Neuropsychopharmacol Hung. 2012 Mar;14(1):19-27.

Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures

Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P; Alzheimer’s Disease Cooperative Study.

Arch Neurol. 2012 Jul;69(7):836-41. doi: 10.1001/archneurol.2012.85.

Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients

Albani D, Martinelli Boneschi F, Biella G, Giacalone G, Lupoli S, Clerici F, Benussi L, Ghidoni R, Galimberti D, Squitti R, Mariani S, Confaloni A, Bruno G, Mariani C, Scarpini E, Binetti G, Magnani G, Franceschi M, Forloni G.

J Alzheimers Dis. 2012;30(4):745-9. doi: 10.3233/JAD-2012-112123.

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E; AAB-001 201/202 Investigators.

Arch Neurol. 2012 Aug;69(8):1002-10. doi: 10.1001/archneurol.2012.90.

Recruitment methods for United States Alzheimer disease prevention trials

Schneider LS.

J Nutr Health Aging. 2012 Apr;16(4):331-5. doi: 10.1007/s12603-012-0011-6.

Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease

Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ.

J Alzheimers Dis. 2012;31(2):335-41. doi: 10.3233/JAD-2012-120508.

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A.

Lancet Neurol. 2012 Jul;11(7):597-604. doi: 10.1016/S1474-4422(12)70140-0. Epub 2012 Jun 6.

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease

Tariot P, Salloway S, Yardley J, Mackell J, Moline M.

BMC Res Notes. 2012 Jun 8;5:283. doi: 10.1186/1756-0500-5-283.

Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention

Hampel H.

Int Psychogeriatr. 2012 Aug;24 Suppl 1:S10-7. doi: 10.1017/S1041610212000579.

Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease

Yao J, Brinton RD.

Adv Pharmacol. 2012;64:327-71. doi: 10.1016/B978-0-12-394816-8.00010-6.

Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in Alzheimer's disease

Grela A, Turek A, Piekoszewski W.

Clin Chem Lab Med. 2012 Feb 11;50(8):1297-304. doi: 10.1515/cclm-2011-0550.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42

Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, Carrillo MC, Gobom J, Heath T, Jenkins R, Jeromin A, Kaplow J, Kidd D, Laterza OF, Lockhart A, Lunn MP, Martone RL, Mills K, Pannee J, Ratcliffe M, Shaw LM, Simon AJ, Soares H, Teunissen CE, Verbeek MM, Umek RM, Vanderstichele H, Zetterberg H, Blennow K, Portelius E.

Biomark Med. 2012 Aug;6(4):409-17. doi: 10.2217/bmm.12.39.

Fluid biomarkers in Alzheimer disease

Blennow K, Zetterberg H, Fagan AM.

Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006221. doi: 10.1101/cshperspect.a006221.

Marking the markers of Alzheimer's: too good to diagnose, too bad to use?

Olah Z, Pakaski M, Janka Z, Kalman J.

Neuropsychopharmacol Hung. 2012 Sep;14(3):165-76.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias